Muscle & Nerve

Papers
(The TQCC of Muscle & Nerve is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience183
Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis110
COVID‐19 in patients with myasthenia gravis82
COVID‐19–associated myositis with severe proximal and bulbar weakness80
Muscle ultrasound: Present state and future opportunities80
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled79
Small fiber neuropathy associated with SARS‐CoV‐2 infection67
Metabolic syndrome and peripheral neuropathy62
SARS‐CoV‐2–associated Guillain‐Barré syndrome with dysautonomia61
Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study55
Guidelines on clinical presentation and management of nondystrophic myotonias51
Parsonage Turner syndrome after COVID‐19 vaccination51
Combination molecular therapies for type 1 spinal muscular atrophy50
Post COVID‐19 vaccine small fiber neuropathy49
The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID‐19 pandemic45
Clinical features of LRP4/agrin‐antibody–positive myasthenia gravis: A multicenter study41
Neuralgic amyotrophy following infection with SARS‐CoV‐239
A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis39
Amyotrophic lateral sclerosis care and research in the United States during the COVID‐19 pandemic: Challenges and opportunities38
The Use of Telehealth to Enhance Care in ALS and other Neuromuscular Disorders38
Risk factors for amyotrophic lateral sclerosis: A regional United States case‐control study35
Guillain‐Barré Syndrome in a Patient With Minimal Symptoms of COVID‐19 Infection33
Multisystem proteinopathy: Where myopathy and motor neuron disease converge32
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy29
Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes29
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies29
Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy28
COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course28
Chronic inflammatory demyelinating polyradiculoneuropathy—Diagnostic pitfalls and treatment approach28
Spinal muscular atrophy care in the COVID‐19 pandemic era27
Autonomic neuropathies27
Pure sensory neuralgic amyotrophy in COVID‐19 infection27
(−)‐Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy27
Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients26
Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders26
Neuromuscular amyloidosis: Unmasking the master of disguise23
Emerging technologies in neuromuscular ultrasound23
Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials23
Influence of limb position on assessment of nerve mechanical properties by using shear wave ultrasound elastography23
Nerve biopsy: Current indications and decision tools22
Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease22
Diabetic neuropathies22
Melatonin may slow disease progression in amyotrophic lateral sclerosis: Findings from the Pooled Resource Open‐Access ALS Clinic Trials database22
COVID‐19‐associated myositis may be dermatomyositis21
Satisfaction with ankle foot orthoses in individuals with Charcot‐Marie‐Tooth disease21
Sleep disorders in myotonic dystrophies21
The future of upper extremity rehabilitation robotics: research and practice21
Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000‐201521
Long‐term strength and functional status in inclusion body myositis and identification of trajectory subgroups20
Assessment of dysarthria and dysphagia in patients with amyotrophic lateral sclerosis: Review of the current evidence20
Diffusion tensor imaging reveals changes in non‐fat infiltrated muscles in late onset Pompe disease20
Diagnostic criteria for idiopathic small fiber neuropathy: A systematic review19
Anti‐cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis19
Shear wave elastography of the median nerve: A mechanical study19
A well‐tolerated core needle muscle biopsy process suitable for children and adults19
Non‐length‐dependent small fiber neuropathy: Not a matter of stockings and gloves19
Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes18
Acute‐onset polyradiculoneuropathy after SARS‐CoV2 vaccine in the West and North Midlands, United Kingdom18
Utilization of MG‐ADL in myasthenia gravis clinical research and care18
Ultrasound can differentiate inclusion body myositis from disease mimics18
Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 118
Traumatic injury to peripheral nerves18
Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy17
TS‐HDS and FGFR3 antibodies in small fiber neuropathy and Dysautonomia17
Nivolumab‐associated Lambert‐Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor17
Management challenges for chronic dysimmune neuropathies during the COVID‐19 pandemic16
Regenerative peripheral nerve interface free muscle graft mass and function16
A study of impairments in oculopharyngeal muscular dystrophy16
Practical guidance for managing electromyography requests and testing during the COVID‐19 pandemic16
Upper trunk brachial plexopathy as a consequence of prone positioning due to SARS‐CoV‐2 acute respiratory distress syndrome16
Skeletal muscle magnetic resonance imaging in Pompe disease16
Muscle fiber size in healthy children and adults in relation to sex and fiber types16
The Duke myasthenia gravis clinic registry: I. Description and demographics16
Smartphone data during the COVID‐19 pandemic can quantify behavioral changes in people with ALS16
Walking activity in a large cohort of boys with Duchenne muscular dystrophy15
Different trajectories in upper limb and gross motor function in spinal muscular atrophy15
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG‐CE)15
The Spinal Muscular Atrophy Health Index: A novel outcome for measuring how a patient feels and functions15
COVID‐19 in muscle‐specific kinase myasthenia gravis: A case report15
Evaluation of persons with suspected lumbosacral and cervical radiculopathy: Electrodiagnostic assessment and implications for treatment and outcomes (Part I)15
Porphyric neuropathy15
Predicting myofiber cross‐sectional area and triglyceride content with electrical impedance myography: A study in db/db mice15
Cold aggravates abnormal excitability of motor axons in oxaliplatin‐treated patients15
Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses14
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment14
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practice14
The CINRG Becker Natural History Study: Baseline characteristics14
Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers14
Differentiated adipose‐derived stem cells promote peripheral nerve regeneration14
Association of diaphragm thickness and echogenicity with age, sex, and body mass index in healthy subjects13
Knowledge and perceptions of the COVID‐19 pandemic among patients with myasthenia gravis13
Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study13
Influence of ultrasound focus depth on the association between echo intensity and intramuscular adipose tissue13
The use of eculizumab in ventilator‐dependent myasthenia gravis patients13
Is it time to revisit the Boston Carpal Tunnel Questionnaire? New insights from a Rasch model analysis13
Clinical profile and impact of comorbidities in patients with very‐late‐onset myasthenia gravis13
Conference report on contractures in musculoskeletal and neurological conditions13
Risk of thrombotic events after inpatient intravenous immunoglobulin or plasma exchange for neurologic disease: A case‐crossover study13
Minimal important differences and self‐identifying treatment response in chronic inflammatory demyelinating polyneuropathy13
Estimating myofiber cross‐sectional area and connective tissue deposition with electrical impedance myography: A study in D2mdx mice13
Brain‐computer interfaces for amyotrophic lateral sclerosis13
Rituximab in late‐onset myasthenia gravis is safe and effective13
Guidance for resumption of routine electrodiagnostic testing during the COVID‐19 pandemic12
Lipocalin‐2 is increased in amyotrophic lateral sclerosis12
Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy12
Small fiber neuropathy: Swiss cohort characterization12
Myasthenia gravis and pregnancy12
Risdiplam in non‐sitter patients aged 16 years and older with 5q spinal muscular atrophy12
Fatigue in chronic inflammatory demyelinating polyneuropathy12
A temporal association between COVID‐19 vaccination and immune‐mediated necrotizing myopathy12
Immune‐mediated necrotizing myopathy: Unusual presentations of a treatable disease12
Glycerophospholipid profile alterations are associated with murine muscle‐wasting phenotype11
Differential involvement of myelinated and unmyelinated nerve fibers in painful diabetic polyneuropathy11
Mechanisms underlying immobilization‐induced muscle pain in rats11
Motor axonal neuropathy associated with GNE mutations11
Clinical correlates of fatigue in chronic inflammatory demyelinating polyneuropathy11
Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy11
Immune‐mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor‐binding domain of SARS‐CoV‐2 and signal recognition particle11
Imaging of neuralgic amyotrophy in the acute phase11
COVID‐19–accelerated disease progression in two patients with amyotrophic lateral sclerosis11
Myasthenic crisis11
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial11
Intrathecal delivery of nusinersen in individuals with complicated spines11
Creatine kinase‐MM concentration in dried blood spots from newborns and implications for newborn screening for Duchenne muscular dystrophy10
Label‐free histomorphometry of peripheral nerve by stimulated Raman spectroscopy10
Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study10
Diagnostic accuracy of gray scale muscle ultrasound screening for pediatric neuromuscular disease10
Daily grip strength response to intravenous immunoglobulin in chronic immune neuropathies10
2020 Virtual AANEM Annual Meeting Abstract Guide10
Epidemiological trends of Bell's palsy treated with steroids in Korea between 2008 and 201810
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study10
Post–COVID‐19 vaccine small‐fiber neuropathy and tinnitus treated with plasma exchange10
Myopathies featuring early or prominent dysphagia10
Delays in pulmonary decline in eteplirsen‐treated patients with Duchenne muscular dystrophy10
Anti‐calcitonin gene–related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache10
Thymoma pathology and myasthenia gravis outcomes10
Cross‐sectional area in median and ulnar nerve ultrasound correlates with hand volume10
Cardiomyopathy in limb girdle muscular dystrophy R9, FKRP related10
Temporal evolution of nerve conduction study abnormalities in anti‐myelin‐associated glycoprotein neuropathy10
Differences in voluntary and reflexive cough strength in individuals with amyotrophic lateral sclerosis and healthy adults10
Selecting disease‐modifying medications in 5q spinal muscular atrophy10
Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?10
Assessment of feasibility and utility of universal referral to specialty palliative care in a multidisciplinary amyotrophic lateral sclerosis clinic: A cohort study10
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudy10
Ganglioside complex antibodies in an Indian cohort of Guillain‐Barré syndrome9
Risdiplam for the treatment of adults with spinal muscular atrophy: Experience of the Northern Ireland neuromuscular service9
Cardiac findings in pediatric patients with spinal muscular atrophy types 2 and 39
Laboratory monitoring of nusinersen safety9
Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: A European collaborative study9
Imaging and treatment of phrenic nerve hourglass‐like constrictions in neuralgic amyotrophy9
A novel method to quantify cutaneous vascular innervation9
Update on immune‐mediated therapies for myasthenia gravis9
Utility of neuromuscular ultrasound in the investigation of common mononeuropathies in everyday neurophysiology practice9
Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID‐199
Infection rate, mortality and characteristics of veterans with amyotrophic lateral sclerosis with COVID‐199
Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis9
Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles9
Association of genetic mutations and loss of ambulation in childhood‐onset dystrophinopathy9
Screening for oropharyngeal dysphagia in adult patients with neuromuscular diseases using the Sydney Swallow Questionnaire9
Identifying putative cerebrospinal fluid biomarkers of amyotrophic lateral sclerosis in a north Indian population9
Diabetic polyneuropathy and the risk of developing carpal tunnel syndrome: A nationwide, population‐based study9
Risk factors for mechanical ventilation in children with Guillain‐Barré syndrome9
Quantitative muscle MRI as a sensitive marker of early muscle pathology in myotonic dystrophy type 19
Myopathies with finger flexor weakness: Not only inclusion‐body myositis9
Short‐term effect of low‐dose rituximab on myasthenia gravis with muscle‐specific tyrosine kinase antibody9
Motor unit number index in children with later‐onset spinal muscular atrophy9
Form factor analysis of the surface electromyographic interference pattern8
Using MRI to quantify skeletal muscle pathology in Duchenne muscular dystrophy: A systematic mapping review8
Age‐related changes in appendicular lean mass in males with Duchenne muscular dystrophy: A retrospective review8
Retrospective study on the safety of COVID‐19 vaccination in myasthenia gravis8
The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid‐induced osteoporosis8
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis8
Muscle architecture is associated with muscle fat replacement in Duchenne and Becker muscular dystrophies8
Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy8
Evidence‐based guideline: Neuromuscular ultrasound for the diagnosis of ulnar neuropathy at the elbow8
Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation8
Assessment of thrombocytopenia, sleep apnea, and cardiac involvement in GNE myopathy patients8
Variability in electrodiagnostic findings associated with neurogenic thoracic outlet syndrome8
Charcot–Marie–Tooth disease type 1A: Longitudinal change in nerve ultrasound parameters8
The cumulative incidence of dysphagia and dysphagia‐free survival in persons diagnosed with amyotrophic lateral sclerosis8
Magnetic resonance imaging of enhanced nerve repair with mesenchymal stem cells combined with microenvironment immunomodulation in neurotmesis8
A double‐blind placebo‐controlled pilot study of immunoglobulin for small fiber neuropathy associated with TS‐HDS and FGFR‐3 autoantibodies8
Ultra–high‐frequency ultrasound imaging of sural nerve: A comparative study with nerve biopsy in progressive neuropathies8
Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy8
Telephone consultation for myasthenia gravis care during the COVID‐19 pandemic: Assessment of a novel virtual myasthenia gravis index8
Cardiac and pulmonary findings in dysferlinopathy: A 3‐year, longitudinal study8
The Notch signaling pathway in skeletal muscle health and disease8
Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy8
An expanded access protocol of RT001 in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor8
Spinal nerve pathology in Guillain‐Barré syndrome associated with COVID‐19 infection8
Dominant and recessive congenital myasthenic syndromes caused by SYT2 mutations8
Incidence and prevalence of immune‐mediated necrotizing myopathy in adults in Olmsted County, Minnesota8
Yes, we can: Neuromuscular examination by telemedicine8
Sensitivity and specificity of repetitive nerve stimulation with lower cutoffs for abnormal decrement in myasthenia gravis8
Recombinant human insulin‐like growth factor‐1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy8
Location‐dependent change of median nerve mobility in the carpal tunnel of patients with carpal tunnel syndrome7
Guidelines for genetic testing of muscle and neuromuscular junction disorders7
Compound muscle action potential scan and MScanFit motor unit number estimation during Wallerian degeneration after nerve transections7
Identifying jitter outliers in single fiber electromyography: Comparison of four methods7
mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis7
A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians and society, part 17
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old7
Creating stem cell‐derived neuromuscular junctions in vitro7
EF hand‐like motif mutations of Nav1.4 C‐terminus cause myotonic syndrome by impairing fast inactivation7
Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment7
Genotype‐related respiratory progression in Duchenne muscular dystrophy—A multicenter international study7
Sensory nerve regeneration and reinnervation in muscle following peripheral nerve injury7
hnRNP L is essential for myogenic differentiation and modulates myotonic dystrophy pathologies7
The senile hand: Age effects on intrinsic hand muscle CMAP amplitudes influence split‐hand index calculations7
An integrated approach to the evaluation of patients with asymptomatic or minimally symptomatic hyperCKemia7
Fasciculation frequency at the biceps brachii and brachialis muscles is associated with amyotrophic lateral sclerosis disease burden and activity7
Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec‐xioi in a premature neonate with type 1 spinal muscular atrophy7
Hereditary myopathies associated with hematological abnormalities7
Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis7
A telephonic single breath count test for screening of exacerbations of myasthenia gravis: A pilot study7
Relative effects of forced vital capacity and ALSFRS‐R on survival in ALS7
Investigating the possible association between NLRP3 gene polymorphisms and myasthenia gravis7
Neutralizing BDNF and FGF2 injection into denervated skeletal muscle improve recovery after nerve repair7
Quantitative T2‐mapping magnetic resonance imaging for assessment of muscle motor unit recruitment patterns7
Small fiber neuropathy underlying dysautonomia in COVID‐19 and in post‐SARS‐CoV‐2 vaccination and long‐COVID syndromes7
Lateral femoral cutaneous neuropathy caused by prone positioning to treat COVID‐19‐associated acute respiratory distress syndrome6
Atypical presentations of inclusion body myositis: Clinical characteristics and long‐term outcomes6
Muscle biopsy and MRI findings in ANO5‐related myopathy6
Nodal conduction block: A unifying concept6
Causes and consequences of diagnostic delay in Guillain‐Barré syndrome in a UK tertiary center6
Small Fiber Neuropathy and SARS‐CoV‐2 Infection. Another piece in the long COVID puzzle?6
Immune‐mediated neuromuscular complications of graft‐versus‐host disease6
Home‐based gait analysis as an exploratory endpoint during a multicenter phase 1 trial in limb girdle muscular dystrophy type R2 and facioscapulohumeral muscular dystrophy6
A standardized ultrasound approach in neuralgic amyotrophy6
Validation of myasthenia gravis diagnosis in the older Medicare population6
Hourglass‐like constrictions on MRI are common in electromyography‐confirmed cases of neuralgic amyotrophy (Parsonage–Turner syndrome): A tertiary referral center experience6
AANEMIFCN Glossary of Terms in Neuromuscular Electrodiagnostic Medicine and Ultrasound6
Positive acetylcholine receptor antibody in nonmyasthenic patients6
Peripheral nerve morphology and intraneural blood flow in chronic kidney disease with and without diabetes6
Efficacy of electrical stimulation of denervated muscle: A multicenter, double‐blind, randomized clinical trial6
Reliability and construct validity of the Duchenne Video Assessment6
Early initiation of riluzole may improve absolute survival in amyotrophic lateral sclerosis6
Autoantibodies in Japanese patients with ocular myasthenia gravis6
Methocarbamol blocks muscular Nav1.4 channels and decreases isometric force of mouse muscles6
Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy6
Krüppel‐like factor 10 regulates the contractile properties of skeletal muscle fibers in mice6
Delivering multidisciplinary neuromuscular care for children via telehealth6
Management of Spinal Muscular Atrophy in the Adult Population6
Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy6
Histone acetyltransferase inhibition rescues differentiation of emerin‐deficient myogenic progenitors6
Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments6
T‐box transcription factor 21 is expressed in terminal Schwann cells at the neuromuscular junction6
Expanding the clinical and genetic spectrum of pathogenic variants in STIM16
Neuromuscular ultrasound competency assessment: Consensus‐based survey6
Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease6
0.061626195907593